Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Posdinemab - Johnson & Johnson Innovative Medicine

Next Previous
Drug Profile

Posdinemab - Johnson & Johnson Innovative Medicine

Alternative Names: Anti-phospho-tau mAb; JNJ-3657; JNJ-63733657

Latest Information Update: 05 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 05 Sep 2025 Janssen Cilag International completes a phase I trial in Alzheimer's Disease (In volunteers, In adults, In the elderly) in Belgium (IV, Infusion) (SC, Infusion) (CTIS2024-513656-15-00)
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In volunteers, In adults) in China (IV, Infusion)
  • 25 Mar 2025 Janssen Cilag International initiates the phase I trial in Alzheimer's disease (Early-stage disease) in Netherlands and France (IV) (CTIS2024-514634-20-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top